2022
The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Kanbay M, Copur S, Siriopol D, Yildiz A, Berkkan M, Popa R, Hasbal N, Ortiz A, Perazella M. The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Clinical Kidney Journal 2022, 16: 817-826. PMID: 37151409, PMCID: PMC10157786, DOI: 10.1093/ckj/sfac194.Peer-Reviewed Original ResearchAcute kidney injuryImmune checkpoint inhibitorsEffect of AKICheckpoint inhibitorsCancer patientsKidney injuryDevelopment of AKISystematic reviewImmune checkpoint inhibitor therapySevere acute kidney injuryPersistent kidney dysfunctionSevere AKI patientsCheckpoint inhibitor therapyRisk of deathNon-randomized studiesCochrane Library databasesRisk of mortalityNovel therapeutic approachesWeb of ScienceAKI patientsICPI treatmentCause mortalityInhibitor therapyKidney dysfunctionMortality outcomesMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activation
2000
Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
Abu-Alfa A, Cruz D, Perazella M, Mahnensmith R, Simon D, Bia M. Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. American Journal Of Kidney Diseases 2000, 35: 1076-1082. PMID: 10845820, DOI: 10.1016/s0272-6386(00)70043-6.Peer-Reviewed Original ResearchMeSH KeywordsAnemiaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBlood TransfusionCross-Over StudiesDiabetes ComplicationsDrug ResistanceEpoetin AlfaErythropoietinFemaleFollow-Up StudiesHematinicsHematocritHospitalizationHumansInfectionsKidney Failure, ChronicLisinoprilMaleMiddle AgedProspective StudiesRecombinant ProteinsRenal DialysisTime FactorsConceptsACE inhibitor therapyACE inhibitorsHemodialysis patientsRHuEPO resistanceInhibitor therapyRecombinant human erythropoietin resistanceRecombinant human erythropoietin (rHuEPO) requirementsBlood pressure controlChronic renal failureDuration of infectionRHuEPO doseTransfusion requirementsErythropoietin resistanceRenal failureDialysis patientsHospitalization daysLaboratory parametersRHuEPO dosesAntihypertensive agentsCrossover studyErythropoietin requirementsInclusion criteriaPatientsAverage ageEnzyme inhibitors
1996
Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance?
Cruz D, Perazella M, Abu-Alfa A, Mahnensmith R. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance? American Journal Of Kidney Diseases 1996, 28: 535-540. PMID: 8840943, DOI: 10.1016/s0272-6386(96)90464-3.Peer-Reviewed Original ResearchConceptsChronic hemodialysis patientsEnzyme inhibitor therapyACE inhibitorsHemodialysis patientsInhibitor therapySevere anemiaGroup 2Group 1End-stage renal diseaseExacerbation of anemiaSuppression of angiotensinChronic renal failureCongestive heart failureTherapy of anemiaBone marrow responseSignificant differencesRed blood cell productionRecombinant human EpoRHuEPO responseChronic hemodialysisErythropoietin resistanceRenal transplantationBaseline characteristicsHospital daysRenal failure